Author(s):
Yin Myo Thant, Mohammad Chand Jamali, Rabindra Dev Prasad, Srikumar Chakravarthi, Yuldashev Bakhrom, Nikolaus Syrmos, Ms. Shokhida Rasulova Shukhrat Kizi
Email(s):
tthant273@gmail.com , mjamali68@gmail.com , rabindra.prasad@newinti.edu.my , srikumarc@segi.edu.my , baxrom@mamunedu.uz , milanako76@yahoo.gr , shohida98@gmail.com
DOI:
10.52711/0974-360X.2026.00343 
Address:
~7
1Department of Education and Liberal Arts, INTI International University, Malaysia.
2Faculty of Medical and Health Sciences, Liwa College, Al Ain, Abu Dhabi, United Arab Emirates
3Dean, Faculty of Education and Liberal Arts INTI International University, Malaysia.
4Deputy Vice Chancellor (Academic, Research, Innovation), SEGi University, Selangor, Malaysia.
5DSC, Professor, Dean of the Faculty of Medicine, Mamun University, Khiva, Uzbekistan.
6Human Performance and Health, Aristotle University of Thessaloniki, Thesaaloniki, Macedonia, Greece.
7Department of Education and Liberal Arts, INTI International University, Malaysia.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Antimicrobial resistance (AMR) is becoming an international threat leading to the failure of modern medicine as well as the progress toward the United Nations Sustainable Development Goals (SDGs), specifically SDG 3 (Good Health and Well-being), SDG 6 (Clean Water and Sanitation), and SDG 12 (Responsible Consumption and Production). AMR is developed when microorganisms become resistant to antimicrobial drugs through evolutions and becomes ineffective to the treatments thus causing high mortality, prolonged hospital stays, and escalated health expenditures. What makes this crisis grow are factors including the abuse of antibiotics usage both in the health of humans and animals, the poor regulation of such use, poor sanitation, and even a general unawareness in developing and middle-income countries. Resurgent surveillance data indicate high levels of resistance to common pathogens such as Escherichia coli, Klebsiella pneumonia and MRSA among others across the regions. An AMR solution would demand a One Health approach, which addresses the solutions to human, animal, and environmental health. The most important of them are antimicrobial stewardship programs (ASP), better diagnostics, infection control, and investment in new therapeutics. To curb the spread of AMR, efficient policy frameworks, international cooperation and community participation are essential. Unless action is taken immediately and in organized effort, AMR will represent 10 million deaths per year by 2050, with most falls being on vulnerable populations. The fight against AMR is a must to have fair, stable, and sustainable systems of healthcare in line with the global development goals.
Cite this article:
Yin Myo Thant, Mohammad Chand Jamali, Rabindra Dev Prasad, Srikumar Chakravarthi, Yuldashev Bakhrom, Nikolaus Syrmos, Ms. Shokhida Rasulova Shukhrat Kizi. A Crossroads of Global Health and Sustainability in the point of Antimicrobial Resistance. Research Journal Pharmacy and Technology. 2026;19(5):2397-6. doi: 10.52711/0974-360X.2026.00343
Cite(Electronic):
Yin Myo Thant, Mohammad Chand Jamali, Rabindra Dev Prasad, Srikumar Chakravarthi, Yuldashev Bakhrom, Nikolaus Syrmos, Ms. Shokhida Rasulova Shukhrat Kizi. A Crossroads of Global Health and Sustainability in the point of Antimicrobial Resistance. Research Journal Pharmacy and Technology. 2026;19(5):2397-6. doi: 10.52711/0974-360X.2026.00343 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-64
REFERENCE:
1. World Health Organization. Priority medicines for Europe and the world [Internet]. Kaplan W, Laing R, editors. Geneva: World Health Organization; 2004 [cited 2023 Aug 25]. Available from: https://iris.who.int/handle/10665/68769?show=full
2. Rehman MT, Faheem M, Khan AU. An insight into the biophysical characterization of different states of cefotaxime hydrolyzing β-lactamase 15 (CTX-M-15). J Biomol Struct Dyn. 2015; 33(4): 625–38.
3. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003; 36(Suppl 1):S11–23.
4. Muteeb G, Alsultan A, Farhan M, Aatif M. Risedronate and methotrexate are high-affinity inhibitors of New Delhi metallo-β-lactamase-1 (NDM-1): a drug repurposing approach. Molecules. 2022; 27(4): 1283.
5. Khan AU, Rehman MT. Role of non-active-site residue Trp-93 in the function and stability of New Delhi metallo-β-lactamase 1. Antimicrob Agents Chemother. 2016;60(1):356–60.
6. Gould K. Antibiotics: from prehistory to the present day. J Antimicrob Chemother. 2016; 71(3): 572–5.
7. Clardy J, Fischbach MA, Currie CR. The natural history of antibiotics. Curr Biol. 2009; 19(11): R437–41.
8. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzæ. Br J Exp Pathol. 1929; 10(3): 226–36.
9. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015; 28(3): 603–61.
10. Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A, et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother. 2012; 67(4): 802–9.
11. Rossolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008; 14(Suppl 1): 33–41.
12. Hristea A, Olaru ID, Adams-Sapper S, Riley LW. Characterization of ESBL-producing Escherichia coli and Klebsiella pneumoniae from bloodstream infections in three hospitals in Bucharest, Romania: a preliminary study. Infect Dis (Lond). 2015; 47(1): 46–51.
13. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015; 13(1): 42–51.
14. Peterson E, Kaur P. Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens. Front Microbiol. 2018; 9: 2928.
15. Vega NM, Gore J. Collective antibiotic resistance: mechanisms and implications. Curr Opin Microbiol. 2014; 21: 28–34.
16. Akiba M, Sekizuka T, Yamashita A, Kuroda M, Fujii Y, Murata M, et al. Distribution and relationships of antimicrobial resistance determinants among extended-spectrum-cephalosporin-resistant or carbapenem-resistant Escherichia coli isolates from rivers and sewage treatment plants in India. Antimicrob Agents Chemother. 2016; 60(5): 2972–80.
17. Heddle J, Maxwell A. Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother. 2002; 46(6): 1805–15.
18. Bello-López JM, Cabrero-Martínez OA, Ibáñez-Cervantes G, Hernández-Cortez C, Pelcastre-Rodríguez LI, Gonzalez-Avila LU, et al. Horizontal gene transfer and its association with antibiotic resistance in the genus Aeromonas spp. Microorganisms. 2019; 7(9): 363.
19. Zhang QY, Yan ZB, Meng YM, Hong XY, Shao G, Ma JJ, et al. Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil Med Res. 2021; 8(1): 48.
20. Racz B, Spengler G. Repurposing antidepressants and phenothiazine antipsychotics as efflux pump inhibitors in cancer and infectious diseases. Antibiotics. 2023; 12(1): 137.
21. Mayorga-Ramos A, Zúñiga-Miranda J, Carrera-Pacheco SE, Barba-Ostria C, Guamán LP. CRISPR-Cas-based antimicrobials: design, challenges, and bacterial mechanisms of resistance. ACS Infect Dis. 2023; 9(7): 1283–302.
22. Martínez JL, Rojo F. Metabolic regulation of antibiotic resistance. FEMS Microbiol Rev. 2011; 35(5): 768–89.
23. Sifri Z, Chokshi A, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Glob Infect Dis. 2019; 11(1): 36–42.
24. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016; 387(10014): 176–87.
25. Baekkeskov E, Rubin O, Munkholm L, Zaman W. Antimicrobial resistance as a global health crisis. In: Stern E, editor. Oxford research encyclopedia of politics. Oxford: Oxford University Press; 2020. p. 1–24.
26. Hassan B, Qadri H, Ali MN, Khan NA, Yatoo AM. Impact of climate change on freshwater ecosystem and its sustainable management. In: Ansari AA, Gill SS, editors. Fresh water pollution dynamics and remediation. Singapore: Springer; 2020. p. 49–78.
27. Woolhouse M, Ward M, Van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1670): 20140083.
28. Gilbert W, Thomas LF, Coyne L, Rushton J. Mitigating the risks posed by intensification in livestock production: the examples of antimicrobial resistance and zoonoses. Animal. 2021; 15(2): 100123.
29. Irfan S, Alatawi AMM. Aquatic ecosystem and biodiversity: a review. Open J Ecol. 2019; 9(1): 1–13.
30. Venter H. Reversing resistance to counter antimicrobial resistance in the World Health Organisation’s critical priority of most dangerous pathogens. Biosci Rep. 2019; 39(2): BSR20180474.
31. Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance—a threat to the world’s sustainable development. Ups J Med Sci. 2016; 121(3): 159–64.
32. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ. 2009; 180(4): 408–15.
33. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol. 2008; 11(4): 393–400.
34. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev. 2021; 34(1): e00115–20.
35. Tao S, Chen H, Li N, Liang W. The application of the CRISPR-Cas system in antibiotic resistance. Infect Drug Resist. 2022; 15: 4155–68.
36. Gholizadeh P, Köse Ş, Dao S, Ganbarov K, Tanomand A, Dal T, et al. How CRISPR-Cas’s system could be used to combat antimicrobial resistance. Infect Drug Resist. 2020; 13: 1111–21.
37. Bergman P, Raqib R, Rekha RS, Agerberth B, Gudmundsson GH. Host-directed therapy against infection by boosting innate immunity. Front Immunol. 2020; 11: 1209.
38. Bhattacharyya M, Debnath AK, Todi SK. Clostridium difficile and antibiotic-associated diarrhea. Indian J Crit Care Med. 2020; 24(Suppl 4): S162–7.
39. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine. 2017; 12: 1227–49.
40. Yeh YC, Huang TH, Yang SC, Chen CC, Fang JY. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front Chem. 2020;8:286.
41. Aatif M, Raza MA, Javed K, Nashre-ul-Islam SM, Farhan M, Alam MW. Potential nitrogen-based heterocyclic compounds for treating infectious diseases: a literature review. Antibiotics. 2022; 11(12): 1750.
42. Sleeman JM, DeLiberto T, Nguyen N. Optimization of human, animal, and environmental health by using the One Health approach. J Vet Sci. 2017; 18(3): 263–8.
43. Zulak KG, Cox BA, Tucker MA, Oliver RP, Lopez-Ruiz FJ. Improved detection and monitoring of fungicide resistance in Blumeria graminis f. sp. hordei with high-throughput genotype quantification by digital PCR. Front Microbiol. 2018; 9: 706.
44. Gupta E, Saxena J, Kumar S, Sharma U, Rastogi S, Srivastava VK, et al. Fast track diagnostic tools for clinical management of sepsis: paradigm shift from conventional to advanced methods. Diagnostics (Basel). 2023; 13(2): 277.
45. Pierce J, Stevens MP. The emerging role of telehealth in antimicrobial stewardship: a systematic review and perspective. Curr Treat Options Infect Dis. 2021; 13(4): 175–91.
46. Galhano BSP, Ferrari RG, Panzenhagen P, de Jesus ACS, Conte-Junior CA. Antimicrobial resistance gene detection methods for bacteria in animal-based foods: a brief review of highlights and advantages. Microorganisms. 2021; 9(5): 923.
47. Ahmed Mahedi MR, Mounich K, Hsu C-Y, Rahman Bhuiyan J, Jasim IK, Othman Mahjoob Khalaf O, et al. Cefiderocol (CFDC): A spy antibiotic future replacement of carbapenem. Res J Pharm Technol. 2023; 16(11): 5492–6. https://doi.org/10.52711/0974-360x.2023.00888
48. Afrin S, Hasan MS, Ahmed Mahedi MR, Chandra Kuri O, Iqbal H, Jawad Kadham M, et al. Eltrombopag Olamine in dengue fever: Systematic review of clinical trials and beyond. Res J Pharm Technol. 2024; 17(6): 2778–82. https://doi.org/10.52711/0974-360x.2024.00436
49. Katale BZ, Mbugi EV, Keyyu JD, Fyumagwa RD, Rweyemamu MM, van Helden PD, et al. One Health approach in the prevention and control of mycobacterial infections in Tanzania: lessons learnt and future perspectives. One Health Outlook. 2019; 1(1): 2.
50. Singh S. Conventional infection prevention and control practices in post-antibiotic era: a perspective. J Sci Res. 2020; 64(2): 167–74.
51. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2018. Stockholm: ECDC; 2019.
52. Alkatheri AH, Alameri SS, Abushelaibi A, Loh J-Y, Cheng W-H, Molouki A, et al. Plants from forest to bench to bedside: the clinical application of botanical antimicrobial compounds. Minerva Biotechnol Biomol Res. 2025; 37(1). https://doi.org/10.23736/s2724-542x.24.03137-7